High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C

Journal of Clinical Investigation

Volumn 103, Issue 2, 1999, Pages 219-227

  Griffin, John H ^a   Kojima, Kazuhisa ^a   Banka, Carole L ^a   Curtiss, Linda K ^a   Fernández, José A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; APOLIPOPROTEIN A1; BLOOD CLOTTING FACTOR 5A; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID; PROTEIN S; THROMBIN;

ANTICOAGULATION; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PHOSPHOLIPID VESICLE; PLASMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTHROMBIN TIME; THROMBOSIS;

EID: 0032897471     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI5006     Document Type: Article

References (60)

1. Gordon, D.J., et al. 1989. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 79:8-15.
2. Barter, P.J., and Rye, K.-A. 1996. High density lipoproteinsand coronary heart disease. Atherosclerosis. 121:1-12.
3. Tall, A.R. 1990. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J. Clin. Invest. 86:379-384.
4. Tribble, D.L., and Krauss, R.M. 1993. HDL and coronary artery disease. Adv. Intern. Med. 38:1-29.
5. Miller, N.E., La Ville, A., and Crook, D. 1985. Direct evidence that reverse cholesterol transport is mediated by high-density lipoprotein in rabbit. Nature. 314:109-111.
6. Fielding, C.J., and Fielding, P.E. 1995. Molecular physiology of reverse cholesterol transport. J. Lipid Res. 36:211-228.
7. Parthasarathy, S., Barnett, J., and Fong, L.G. 1990. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim. Biophys. Acta. 1044:275-283.
8. Banka, C.L. 1996. High density lipoprotein and lipoprotein oxidation. Curr. Opin. Lipidol. 7:139-142.
9. Berliner, J.A., et al. 1995. Atherosclerosis; basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 91:2488-2496.
10. Barter, P.J., et al. 1998. Antiatherogenic effects of high-density lipoproteins: mechanisms. In Atherosclerosis XI. B. Jacotot, D. Mathé, and J.-C. Fruchart, editors. Elsevier Science. Singapore. 125-133.
11. Ross, R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:801-809.
12. Miller, G.J. 1995. Lipoproteins and thrombosis: effects of lipid lowering Curr. Opin. Lipidol. 6:38-42.
13. Miller, G.J., Bauer, K.A., Barzegar, S., Cooper, J.A., and Rosenberg, R.D. 1996. Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease. Thromb. Haemost. 75:767-771.
14. Mitropoulos, K.A. 1994. Lipid-thrombosis interface. Br. Med. J. 50:813-832.
15. Hamsten, A., Karpe, F., Bȧvenholm, P., and Silveira, A. 1994. Interactions amongst insulin, lipoproteins and haemostatic function relevant to coronary heart disease. J. Intern. Med. 236:75-88.
16. Marlar, R.A., Kleiss, A.J., and Griffin, J.H. 1982. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood. 59:1067-1072.
17. Esmon, C.T. 1993. Molecular events that control the protein C anticoagulant pathway. Thromb. Haemost. 70:29-35.
18. Dahlbäck, B. 1995. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb. Res. 77:1-41.
19. Griffin, J.H., and Petaja, J. 1997. Activated protein C resistance. In Molecular mechanisms of hypercoaguable states. A.I. Schafer, editor. Landes Bioscience. Austin, TX. 101-123.
20. 506→glutamine mutation. Stroke. 27:1163-1166.
21. van der Bom, J.G., et al. 1996. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann. Intern. Med. 125:265-269.
22. Ridker, P.M., et al. 1995. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N. Engl. J. Med. 332:912-917.
23. Esmon, C.T. 1997. Defects in natural anticoagulant pathways as potential risk factors for myocardial infarction. Circulation. 96:9-11.
24. Bakker, H.M., et al. 1992. The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C. Eur. J. Biochem. 208:171-178.
25. Kalafatis, M., Rand, M.D., and Mann, K.G. 1994. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J. Biol. Chem. 269:31869-31880.
26. R506Q by activated protein C. Biol. Chem. 270:27852-27858.
27. Banka, C.L., Black, A.S., Dyer, C.A., and Curtiss, L.K. 1991. THP-1 cells form foam cells in response to coculture with lipoproteins but not platelets. J. Lipid Res. 32:35-43.
28. Banka, C.L., Bonnet, D.J., Black, A.S., Smith, R.S., and Curtiss, L.K. 1991. Localization of an apolipoprotein A-I epitope critical for activation of lecithin-cholesterol acyltransferase. J. Biol. Chem. 266:23886-23892.
29. Markwell, M.A.K., Haas, S.M., Bieber, L.L., and Tolbert, N.E. 1978. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem. 87:206-210.
30. 506-factor V. Blood. 85:3405-3411.
31. Koedam, J.A., Meijers, J.C.M., Sixma, J.J., and Bouma, B.N. 1988. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J. Clin. Invest. 82:1236-1243.
32. Heeb, M.J., Mesters, R.M., Tans, G., Rosing, J., and Griffin, J.H. 1993. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J. Biol. Chem. 268:2872-2877.
33. Curtiss, L.K., and Edgington, T.S. 1982. Immunochemical heterogeneity of human plasma apolipoprotein B. I. Apolipoprotein B binding of mouse hybridoma antibodies. J. Biol. Chem. 257:15213-15221.
34. Savage, B., Saldivar, E., and Ruggeri, Z.M. 1996. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Villebrand facror. Cell. 84:289-297.
35. Dahlback, B., Carlsson, M., and Svensson, P.J. 1993. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc. Natl. Acad. Sci. USA. 90:1004-1008.
36. Griffin, J.H., Evatt, B., Wideman, C., and Fernández, J.A. 1993. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood. 82:1989-1993.
37. R506Q. J. Biol. Chem. 270:4053-4057.
38. Griffin, J.H., Gruber, A., and Ferńandez, J.A. 1992. Reevaluation of total, free, and bound prorein S and C4b-binding protein levels in plasma anticoagulated with citrate or hirudin. Blood. 79:3203-3211.
39. de Ronde, H. and Bertina, R.M. 1994. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb. Haemost. 72:880-886.
40. Sun, X., Evatt, B., and Griffin, J.H. 1994. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood. 83:3120-3125.
41. Coller, B.S., et al. 1987. Deficiency of plasma protein S, protein C, or antithrombin III and arterial thrombosis. Arteriosclerosis. 7:456-462.
42. Wiesel, M.-L., et al. 1990. Screening of protein S deficiency using a functional assay in patients with venous and arterial thrombosis. Thromb. Res. 58:463-468.
43. Koller, H., et al. 1994. Deficiency of both protein C and protein S in a family with ischemic strokes in young adults. Neurology. 44:1238-1240.
44. Folsom, A.R., Wu, K.K., Rosamond, W.D., Sharrett, A.R., and Chambless, L.E. 1997. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 96:1102-1108.
45. Folsom, A.R., et al. 1998. Prospective study of markers of hemostatic function, inflammation, and endothelial function with risk of ischemic stroke. Circulation. 98:1-207. (Abstr.)
46. Kawasaki, T., et al. 1997. Hypercholesterolemia as a risk factor for deep vein thrombosis. Thromb. Res. 88:67-73.
47. Smirnov, M.D., and Esmon, C.T. 1994. Phosphatidylethanolamine incorporation into vesicles selectively enhances Factor Va inactivation by activated protein C. J. Biol. Chem. 269:816-819.
48. 3 lipid levels in coronary artery disease. Atherosclerosis. 59:131-136.
49. Groener, J.E., Scheck, L.M., van Ramshorst, E., Krauss, X.H., and van tol, A. 1998. Delayed increase in high density lipoproteinphospholipids after ingestion of a fat load in normolipidemic patients with coronary artery disease. Arteriosclerosis. 137:311-319.
50. Kunz, F., Pechlaner, C., Erhart, R., Fend, F., and Mühlberger, V. 1994. HDL and plasma phospholipids in coronary artery disease. Arterioscler. Thromb. 14:1146-1150.
51. Fournier, N., et al. 1997 HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum. Arterioscler. Thromb. Vasc. Biol. 17:2685-2691.
52. Pajkrt, D., et al. 1997. Differential effects of reconstituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxemia. Thromb. Haemost. 77:303-307.
53. Rota, S., McWilliam, N.A., Baglin, T.P., and Byrne, C.D. 1998. Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E. Blood. 91:508-515.
54. Moyer, M.P., et al. 1998. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arteriosder. Thromb. Vasc. Biol. 18:458-465.
55. Silveira, A., et al. 1994. Activation of coagulation factor VII during alimentary lipemia. Arterioscler. Thromb. 14:60-69.
56. Miller, G.J., et al. 1996. Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency. Blood. 87:4187-4196.
57. Cochrane, C.G., and Griffin, J.H. 1980. The biochemistry and pathophysiology of the contact system of plasma. Adv. Immunol. 33:241-306.
58. Bradley, W.A., and Gianturco, S.H. 1988 Vitamin K-dependent proteins bind to very low-density lipoproteins. Semin. Thromb. Hemost. 14:253-257.
59. De Sousa, J.C., et al. 1988. Association between coagulation factors VII and X with triglyceride rich lipoproteins. J. Clin. Pathol. 41:940-944.
60. Xu, N., Dahlbäck, B., Öhlin, A.-K., and Nilsson, Å. 1998. Association of vitamin K-dependent coagulation proteins and C4b binding protein with triglyceride-rich lipoproteins of human plasma. Arterioscler. Thromb. Vasc. Biol. 18:33-39.